156 related articles for article (PubMed ID: 21551002)
1. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer.
Gallo M; De Luca A; Lamura L; Normanno N
Ann Oncol; 2012 Mar; 23(3):597-604. PubMed ID: 21551002
[TBL] [Abstract][Full Text] [Related]
2. The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines.
Fragni M; Bonini SA; Bettinsoli P; Bodei S; Generali D; Bottini A; Spano PF; Memo M; Sigala S
Naunyn Schmiedebergs Arch Pharmacol; 2016 May; 389(5):529-38. PubMed ID: 26905520
[TBL] [Abstract][Full Text] [Related]
3. Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells.
Borghese C; Casagrande N; Pivetta E; Colombatti A; Boccellino M; Amler E; Normanno N; Caraglia M; De Rosa G; Aldinucci D
Oncotarget; 2017 Jun; 8(26):42926-42938. PubMed ID: 28477013
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid prevents the tumor-promoting effects of mesenchymal stem cells via MCP-1 dependent recruitment of macrophages.
Jia XH; Du Y; Mao D; Wang ZL; He ZQ; Qiu JD; Ma XB; Shang WT; Ding D; Tian J
Oncotarget; 2015 Sep; 6(28):26018-28. PubMed ID: 26305552
[TBL] [Abstract][Full Text] [Related]
5. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.
Qiao H; Wang TY; Yan W; Qin A; Fan QM; Han XG; Wang YG; Tang TT
Acta Pharmacol Sin; 2015 Sep; 36(9):1085-98. PubMed ID: 26235741
[TBL] [Abstract][Full Text] [Related]
6. Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-α and the NF-κB pathway.
Katanov C; Lerrer S; Liubomirski Y; Leider-Trejo L; Meshel T; Bar J; Feniger-Barish R; Kamer I; Soria-Artzi G; Kahani H; Banerjee D; Ben-Baruch A
Stem Cell Res Ther; 2015 May; 6(1):87. PubMed ID: 25928089
[TBL] [Abstract][Full Text] [Related]
7. N-cadherin mediates the migration of bone marrow-derived mesenchymal stem cells toward breast tumor cells.
Choi S; Yu J; Kim W; Park KS
Theranostics; 2021; 11(14):6786-6799. PubMed ID: 34093853
[No Abstract] [Full Text] [Related]
8. Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines.
Ibrahim T; Liverani C; Mercatali L; Sacanna E; Zanoni M; Fabbri F; Zoli W; Amadori D
Int J Oncol; 2013 Apr; 42(4):1263-70. PubMed ID: 23403907
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration.
De Luca A; Lamura L; Gallo M; Maffia V; Normanno N
J Cell Biochem; 2012 Nov; 113(11):3363-70. PubMed ID: 22644871
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion.
Rietkötter E; Menck K; Bleckmann A; Farhat K; Schaffrinski M; Schulz M; Hanisch UK; Binder C; Pukrop T
Oncotarget; 2013 Sep; 4(9):1449-60. PubMed ID: 24036536
[TBL] [Abstract][Full Text] [Related]
11. Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model.
Qiao H; Wang TY; Yu ZF; Han XG; Liu XQ; Wang YG; Fan QM; Qin A; Tang TT
Cell Death Dis; 2016 Feb; 7(2):e2094. PubMed ID: 26866274
[TBL] [Abstract][Full Text] [Related]
12. Immune modulation of CD4
Liu H; Wang SH; Chen SC; Chen CY; Lo JL; Lin TM
BMC Immunol; 2016 Nov; 17(1):45. PubMed ID: 27887569
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?
Steinman RA; Brufsky AM; Oesterreich S
Breast Cancer Res; 2012 Sep; 14(5):213. PubMed ID: 23014660
[TBL] [Abstract][Full Text] [Related]
14. Extracellular Ca(2+)-dependent enhancement of cytocidal potency of zoledronic acid in human oral cancer cells.
Inoue S; Arai N; Tomihara K; Takashina M; Hattori Y; Noguchi M
Eur J Pharmacol; 2015 Aug; 761():44-54. PubMed ID: 25934567
[TBL] [Abstract][Full Text] [Related]
15. Krüppel-like factors KLF2 and 6 and Ki-67 are direct targets of zoledronic acid in MCF-7 cells.
Ebert R; Zeck S; Meissner-Weigl J; Klotz B; Rachner TD; Benad P; Klein-Hitpass L; Rudert M; Hofbauer LC; Jakob F
Bone; 2012 Mar; 50(3):723-32. PubMed ID: 22166808
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells.
Liu H; Wang SH; Chen SC; Chen CY; Lin TM
BMC Cancer; 2019 Feb; 19(1):176. PubMed ID: 30808421
[TBL] [Abstract][Full Text] [Related]
17. Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway.
Surmeli Z; Gursoy P; Erdogan AP; Bozkurt E; Atmaca H; Uzunoglu S; Sezgin C; Şanlı UA; Uslu R; Karaca B
Tumour Biol; 2016 Mar; 37(3):3665-73. PubMed ID: 26462835
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages.
Tsagozis P; Eriksson F; Pisa P
Cancer Immunol Immunother; 2008 Oct; 57(10):1451-9. PubMed ID: 18297280
[TBL] [Abstract][Full Text] [Related]
19. BMP9 regulates cross-talk between breast cancer cells and bone marrow-derived mesenchymal stem cells.
Wan S; Liu Y; Weng Y; Wang W; Ren W; Fei C; Chen Y; Zhang Z; Wang T; Wang J; Jiang Y; Zhou L; He T; Zhang Y
Cell Oncol (Dordr); 2014 Oct; 37(5):363-75. PubMed ID: 25209393
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interaction.
Schech AJ; Nemieboka BE; Brodie AH
J Steroid Biochem Mol Biol; 2012 Nov; 132(3-5):195-202. PubMed ID: 22659283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
